When the mail-in ancestry company 23andMe filed for bankruptcy, Regeneron Pharmaceuticals stepped in to snap it up. Though in the end the Tarrytown-based company was outbid, the scenario raised a ...
Genetic information submitted by millions of 23andMe users is now in the hands of pharmaceutical giant Regeneron, following a £200 million acquisition deal. Originally provided by customers seeking ...
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, Inc. tops our list for being one of the most undervalued healthcare stocks ...
23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. Stream Connecticut News for free, 24/7 ...
Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained control over the embattled genetic testing company after her new nonprofit, TTAM Research Institute, outbid Regeneron ...
The sale of 23andMe was finalized this week, following the company filing for bankruptcy in March. The sale was previously approved by a judge. The company was purchased by the nonprofit TTAM Research ...
23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release. The move comes after Regeneron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results